Is rumored pharma target Bausch + Lomb aiming for an IPO instead?

Big Pharma CEOs are throwing cold water on expectations for more medium-sized M&A this year. While analysts see promise for $10 billion deals, executives from Novartis ($NVS) to the newly independent AbbVie ($ABBV) to Sanofi ($SNY) say smaller is beautiful. And now, the CEO of a supposed Big Pharma target--Bausch + Lomb--tells Reuters that he'd prefer to go public rather than sell out.

Now owned by the private equity firm Warburg Pincus, Bausch + Lomb is reportedly up for sale, with one major drugmaker after another rumored to be shopping at the eye-care company. Sanofi, Merck ($MRK), Johnson & Johnson ($JNJ) and Abbott Laboratories ($ABT) (not to be confused with the spun-off AbbVie) are all rumored to be interested parties. Reported asking price? $10 billion or more.

But at the J.P. Morgan Healthcare Conference, Bausch + Lomb CEO Brent Saunders said he's "aspiring to return to public markets," the news service reports. Saunders declined to comment on the reports of a possible sale.

As Reuters notes, some sources have said Warburg Pincus may choose to take Bausch + Lomb public rather than sell the company. And if Saunders really prefers an IPO to a deal, then he must be heartened by the pharma CEOs' comments at J.P. Morgan. If those assessments hold true, then Warburg Pincus may not be able to collect its $10 billion toll--giving Saunders a better chance at his aspirations.

- read the Reuters news

Special Reports: The top M&A dealmakers in biopharma

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.